Date: 14 Feb 2006
Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review
Insulin resistance, which manifests itself as endogenous glucose overproduction and reduced insulin-mediated glucose uptake, is a core defect in type 2 diabetes. Metformin and the peroxisome proliferator-activated receptor-γ agonists, the thiazolidinediones (TZDs), both lower glucose, although their mechanism of action is still subject to debate. This review analyses the evidence relevant to these mechanisms in vivo.
Materials and methods
A systematic search of MEDLINE identified a total of 42 clinical studies that investigated the effects of TZDs (n=23) and/or metformin (n=19) on endogenous glucose production (using tracer glucose techniques) and peripheral glucose disposal (using the euglycaemic–hyperinsulinaemic clamp) in patients with type 2 diabetes (n=549). The original variables assessed were converted into standardised units and their mean group values were listed separately for open and placebo-controlled studies. Statistical analysis was scarried out, treating mean group values as individual values and comparing results (both as absolute values and percentage changes from baseline) across study categories (open vs placebo-controlled, TZDs vs metformin).
Both TZDs and metformin enhance insulin suppression of endogenous glucose production and fasting plasma glucose clearance. TZDs, but not metformin, also improve insulin-mediated glucose uptake at all insulin levels.
In patients with type 2 diabetes, metformin improves fasting hepatic insulin sensitivity and glucose clearance; TZDs improve fasting hepatic insulin sensitivity and glucose clearance, and potentiate glucose disposal under insulinised conditions.
Henry RR (2003) Insulin resistance: from predisposing factor to therapeutic target in type 2 diabetes. Clin Ther 25(Suppl B):B47–B63CrossRef
Cuber JC, Bosshard A, Vidal H, Vega F, Wiernsperger N, Rapin JR (1994) Metabolic and drug distribution studies do not support direct inhibitory effects of metformin on intestinal glucose absorption. Diabetes Metab 20:532–539
Ferrannini E, DeFronzo RA (2004) Insulin actions in vivo: glucose metabolism. In: DeFronzo RA, Ferrannini E, Keek H, Zimmet P (eds) International textbook of diabetes mellitus, 3rd edition. John Wiley and Sons, Chichester, pp 277–302
Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti P; Quartet Study Group (2005) Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double blind randomized trial. J Clin Endocrinol Metab 89:6068–6076CrossRef
McIntyre HD, Ma A, Bird DM, Paterson CA, Ravenscroft PJ, Cameron DP (1991) Metformin increases insulin sensitivity and basal glucose clearance in type 2 (non-insulin dependent) diabetes mellitus. Aust N Z J Med 21:714–719PubMed
Robertson RP, Zhang HJ, Pyzdrowski KL, Walseth TF (1992) Preservation of insulin mRNA levels and insulin secretion in HIT cells by avoidance of chronic exposure to high glucose concentrations. J Clin Invest 90:320–325PubMed
Boden G, Ruiz J, Kim CJ, Chen X (1996) Effects of prolonged glucose infusion on insulin secretion, clearance, and action in normal subjects. Am J Physiol 270:E251–E258PubMed
Hother-Nielsen O, Schmitz O, Andersen PH, Beck-Nielsen H, Pedersen O (1989) Metformin improves peripheral but not hepatic insulin action in obese patients with type II diabetes. Acta Endocrinol (Copenh) 120:257–265
- Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review
Volume 49, Issue 3 , pp 434-441
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Insulin resistance
- Peroxisome proliferator-activated receptor-γ agonists
- Industry Sectors